Prostate Cancer Clinical Trial
Official title:
Phase Ib Study of Monoclonal Antibody to OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer After Systemic Therapy
This clinical trial will examine a novel combination of anti-OX40 to induce proliferation of memory and effector T cells in conjunction with cyclophosphamide (CTX) and radiation to induce tumor antigen release with the overall goal of promoting an immune response against prostate cancer.
A Phase Ib trial design will be employed in patients with metastatic PC who have failed prior
androgen ablation and docetaxel. CTX will be administered also on Day 1. All patients will
receive RT (800 cGy in a single fraction) to up to 3 bone metastatic sites on Day 4 in the
AM. Anti-OX40 at 0.4 mg/kg IV will be given on days 4, 6 and 8. The timing of CTX, RT and
anti-OX40 are based on the pre-clinical models and the observation that the synergies of CTX
and RT are reduced when they are given more than one week after anti-OX40 and are maximized
when given within 3 days of starting anti-OX40. The proposed radiation dose is commonly used
to palliate bone pain in PC and generally will not induce significant cytopenias. The CTX
dose will be escalated in successive cohorts of 3 - 6 patients to assure patient safety. The
dose levels of CTX will be 300, 600 and 900 mg/m2 intravenously in the initial stage of the
study. The range of CTX doses is commonly used in general oncology practice and is not
expected to induce prolonged myelosuppression, although transient cytopenias are likely.
Concurrent CTX and RT has been well-tolerated at much higher dose-intensities than the
investigators are proposing (52-54), thus the investigators are not expecting significant
adverse events from the combination before anti-OX40. As a safety consideration, the
investigators are not giving CTX and RT on the same day as a high proportion of men with
prostate cancer have bone metastases in the pelvis. RT to the pelvis could cause radiation
cystitis that would be exacerbated by the metabolites of CTX (e.g., acrolein) that can
accumulate in the bladder in the 24-36 hours after administration. After the dose-escalation
portion of the trial then up to 20 additional patients can enroll in the study at the maximum
tolerated CTX dose if clinical responses are seen, for a maximum total of 37 patients using a
Simon two-stage design (see Section 10 for details).
The main clinical objective of the trial will be to characterize toxicity and estimate the
response rate of the combination of anti-OX40, CTX and RT. Both radiographic and PSA
responses will be followed. RECIST will be used for radiographic assessment and a significant
PSA response will be defined as a 50% or greater decrease from baseline measured at 3 and 6
weeks after the start of treatment based on the PCWG2 guidelines (55).
Patients will enroll consecutively to each cohort assuming no dose-limiting toxicities. Three
patients will be treated per cohort and if there are no dose-limiting toxicities, then
enrollment to the next cohort can begin. If a dose-limiting toxicity is encountered in the
first three patients in any cohort, then an additional three patients will be enrolled in
that cohort.* This dosing strategy will allow for a three-fold escalation of CTX.
The main hypothesis of this study is that CTX and RT will induce tumor breakdown providing a
source of antigen for self-vaccination and anti-OX40 will amplify CD8-mediated effector
responses across a broad spectrum of prostate cancer antigens resulting in further regression
of prostate cancer. The investigators predict that anti-OX40 will not increase circulating or
intratumoral Treg, and this should help to further augment immune responses.
*For the dose escalation portion of the study, the first 2 patients in any cohort can be
treated on consecutive weeks. If there are no Dose Limiting Toxicities, then the third
patient can begin treatment 28 days after the second patient has completed anti-OX40. If the
third patient has no DLT, then the next cohort can open 28 days after the third patient has
completed anti-OX40. If a DLT occurs with patient 3 in any cohort, then up to 3 more patients
will enroll to the same cohort at a frequency of one patient every 28 days after the previous
patient has completed anti-OX40 assuming no DLT.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |